International Edition
Latest News
Health

CASS4 Gene Helps Brain’s Immune Cells Contain Alzheimer’s Plaques, UVA Study Finds

“These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer’s disease,” said John Lukens, PhD, director of UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases. Researchers at UVA…

CASS4 Gene Helps Brain's Immune Cells Contain Alzheimer's Plaques, UVA Study Finds

“These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer’s disease,” said John Lukens, PhD, director of UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases.

Researchers at UVA Health have discovered that a gene repeatedly linked to Alzheimer’s risk, CASS4, regulates the brain’s immune cells so they can surround and compact toxic amyloid-beta plaques, and that losing its function accelerates plaque spread, neuron damage and cognitive decline in mice, the university announced.

The study, published in the Journal of Experimental Medicine, shifts the prevailing view that CASS4 acts primarily in neurons, showing instead that its main role in Alzheimer’s is through microglia — the brain’s resident immune cells.

Microglia Lose Containment Ability Without CASS4

Microglia normally respond to amyloid-beta deposits by forming protective barriers around them and compressing the plaques into smaller, denser structures that limit damage to surrounding tissue. When UVA researchers disrupted CASS4 in laboratory mice, those microglia struggled to respond to plaques, allowing deposits to expand and spread more aggressively, according to the university’s release.

Plaques accumulated more rapidly, nearby neurons suffered damage, and the animals experienced worsening cognitive function, the researchers found.

Risk Gene’s Function Was Previously Unknown

Genome-wide association studies had repeatedly flagged CASS4 as an Alzheimer’s risk locus, but its biological role in the brain remained a mystery. “Despite CASS4 being an Alzheimer’s risk gene, really nothing is known about what this gene does or how it affects the brain during disease,” said Addie Walsh, a UVA physiology graduate student and first author of the paper.

“These are important findings because they give us new insight into how this understudied AD risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology.”

The Alzheimer's genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis — Journal of Experimental Medicine

Immune Pathway Opens New Therapeutic Avenue

The discovery redirects therapeutic focus from neurons to the brain’s immune system. “Many in the field initially presumed that CASS4 was likely functioning in neurons to influence Alzheimer’s,” Lukens said.

“Our findings shift this paradigm by proving that CASS4 predominantly acts through the immune system. This is particularly exciting, as it has only been in recent years that immune-targeting strategies have been considered for the treatment of neurodegenerative diseases, and this remains an untapped therapeutic avenue with tremendous potential.”

The team is now exploring whether CASS4 plays roles in other neurodegenerative disorders and developing strategies to boost its activity, Lukens said.

Early Biomarker Potential Remains to Be Tested

Defective CASS4 activity could eventually serve as an early-warning biomarker to identify people at risk before serious symptoms develop, the researchers suggest. However, the experiments demonstrating increased plaque buildup, neuronal damage and cognitive decline were conducted in mice, and further research is needed to determine whether targeting CASS4 produces similar protective effects in humans.

Study Details and Funding

The paper, titled “CASS4 regulates microglial response to amyloid-β and protects against Alzheimer’s disease pathogenesis,” was published with DOI 10.1084/jem.20260104.

Co-authors include Benjamin A. Davis, Joshua D. Samuels, William A. Mills III, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo and Lukens. The researchers reported no financial conflicts of interest.

Funding came from the National Institutes of Health’s National Institute on Aging (grants R01AG071996, R01AG087406, RF1AG078684 and R01AG086344), the Cure Alzheimer’s Fund, the Owens Family Foundation, the Harrison Family Foundation, the Rick Sharp Foundation and the Steven A. Newman AD Award.

From Lab to Biotech Institute

The work is part of a broader effort at UVA to translate laboratory discoveries into treatments. Lukens leads the Harrison Family Translational Research Center. He is also a member of UVA’s Center for Brain Immunology and Glia (BIG Center).

Walsh will continue studying microglia in neurodegeneration as a postdoctoral researcher with the Neurodegeneration Team at Novartis in Boston starting at the end of the year.

Alzheimer’s Gene Discovery: What This Means for Patients

What does CASS4 do in the brain? CASS4 helps microglia — the brain’s immune cells — surround and compact amyloid-beta plaques, limiting their spread and protecting nearby neurons.

Is this a cure for Alzheimer’s? No. The findings are from mouse models. Human studies are needed to confirm whether boosting CASS4 activity can slow or prevent the disease in people.

Could CASS4 become a diagnostic marker? Researchers propose that defective CASS4 activity might eventually serve as an early biomarker, but this possibility has not yet been tested in clinical settings.

Lukens has been a faculty member in the UVA School of Medicine’s Department of Neuroscience since 2014. In 2023, his team identified a molecule that orchestrates the immune system’s responses to Alzheimer’s and multiple sclerosis, a finding that could allow doctors to enhance the body’s ability to fight neurological diseases.

He has published more than 70 papers and book chapters and was named a Hartwell Foundation Investigator in 2016. His research at UVA’s Center for Brain Immunology and Glia has received support from the National Institutes of Health, the Owens Family Foundation, the Cure Alzheimer’s Fund, the Alzheimer’s Association and the Department of Defense, among others.

“We are now actively exploring potential roles for CASS4 in multiple other neurodegenerative disorders and developing novel strategies to therapeutically target it,” Lukens said.

About the author: Health Desk

Health Desk at Archynewsy.